New hope for tough prostate cancer: targeted radiation drug enters phase 2 trial

NCT ID NCT06402331

Ongoing Disease control Sponsor: Fusion Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radioactive drug, FPI-2265, in 110 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy. Participants must have already received a similar radioactive treatment. The goal is to find the safest dose and see if it can shrink tumors or lower PSA levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

BAMF Health

Grand Rapids, Michigan, 49503, United States
Biogenix Molecular, LLC

Miami, Florida, 33165, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Hoag Health Center Irvine

Irvine, California, 92618, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016, United States
Memorial Sloan Kettering Cancer Center - NYC

New York, New York, 10065, United States
New Mexico Oncology Hematology Consultants Ltd.

Albuquerque, New Mexico, 87109, United States
Oregon Health and Science University (OHSU, Knight Cancer Center)

Portland, Oregon, 97239-3098, United States
SSM Health Saint Louis University Hospital

St Louis, Missouri, 63104, United States
The University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States
U.T. MD Anderson Cancer Center

Houston, Texas, 77030, United States
UCSF School of Medicine

San Francisco, California, 94143, United States
United Theranostics

Glen Burnie, Maryland, 21061, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States
VA Greater Los Angeles Healthcare System

Los Angeles, California, 90073, United States
VA North Texas Health Care System, Nuclear Medicine Service

Dallas, Texas, 75216, United States
XCancer

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.